^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Renal Cell Carcinoma

    Related cancers:
    15h
    Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC (clinicaltrials.gov)
    P2, N=25, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Lenvima (lenvatinib) • Qibeian (iparomlimab/tuvonralimab)
    20h
    YWHAE-rearranged clear cell sarcoma of kidney: a clinicopathological analysis of seven cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    Definitive diagnosis relies on molecular testing (such as FISH or NGS), which is crucial for differential diagnosis and prognostic evaluation. This subtype of CCSK is commonly associated with advanced clinical stage and early metastasis/recurrence, highlighting the necessity for improving risk stratification and clinical management.
    Retrospective data • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CREBBP (CREB binding protein) • BCOR (BCL6 Corepressor)
    20h
    Clinicopathological characteristics of anaplastic sarcoma of the kidney in children (PubMed, Zhonghua Bing Li Xue Za Zhi)
    ASK in children is a rare DICER1-related tumor, with distinct histologic features and biological behavior. The differential diagnosis includes anaplastic Wilms tumor, clear cell sarcoma of the kidney, etc. Integration of clinical manifestations, histology, immunohistochemistry, and molecular studies may be required to render correct diagnosis.
    Journal
    |
    TP53 (Tumor protein P53) • DICER1 (Dicer 1 Ribonuclease III) • MYOD1 (Myogenic Differentiation 1)
    |
    TP53 mutation
    20h
    Clinicopathological and molecular features of acquired cystic disease-associated renal cell carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
    ACD-RCC is a rare renal cell carcinoma that occurs in patients with end-stage renal disease and has unique morphological features. It is often associated with favorable prognosis and alterations in genes related to the MTOR/TSC pathway or chromatin modification.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • KMT2C (Lysine Methyltransferase 2C) • TSC2 (TSC complex subunit 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • TSC1 (TSC complex subunit 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • MME (Membrane Metalloendopeptidase) • KMT2B (Lysine Methyltransferase 2B) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8) • TFEB (Transcription Factor EB 2)
    |
    TP53 mutation
    20h
    Astragalus polysaccharide enhances the antitumor efficacy of sunitinib in renal cell carcinoma by targeting the ZEB1-SCD1-Wnt/β-Catenin signaling pathway. (PubMed, Int J Biol Macromol)
    Clinical data further verified that high ZEB1 expression is associated with poor prognosis in RCC and that ZEB1 promotes tumor progression by regulating SCD1 to activate the Wnt signaling pathway. In conclusion, APS enhances the sensitivity of RCC to sunitinib by targeting the ZEB1-SCD1-Wnt axis, thus providing a theoretical basis for the clinical application of this combined therapy.
    Journal
    |
    ZEB1 (Zinc Finger E-box Binding Homeobox 1)
    |
    sunitinib
    2d
    Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC (clinicaltrials.gov)
    P2, N=21, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Fumena (vorolanib)
    2d
    ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma. (PubMed, Cancer Res)
    Together, this study underscores the coordinated role of HIFα and ZNF395 in shaping metabolic adaptations in response to hypoxia in VHL-deficient ccRCCs. ZNF395 and HIF are complementary mediators of hypoxia-induced metabolic reprogramming and therapeutic targets in VHL-deficient kidney cancer, with the former regulating glutamine metabolism and the latter regulating glucose metabolism.
    Journal
    |
    EPAS1 (Endothelial PAS domain protein 1)
    2d
    Functionally characterizing the renal cell carcinoma tumor immune microenvironment via patient-derived ex vivo models. (PubMed, Cancer Res Commun)
    PD-1 blockade induced modest T cell activation, whereas VEGFRi downregulated several immune markers, including signaling pathways and immune activation-related cytokines. Our study reveals the suppressive features of the RCC TME and the challenge of fully overcoming it with PD-1 blockade and VEGFRi.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • IL2 (Interleukin 2)
    2d
    Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group. (PubMed, Expert Opin Pharmacother)
    As reported, ongoing phase III clinical trials are set to yield potentially practice-changing results, investigating innovative combinatorial strategies including belzutifan. Ongoing advancement of predictive biomarkers and understanding of resistance mechanisms could improve patient selection and identify new drug targets, thereby increasing the clinical efficacy of belzutifan.
    Journal
    |
    EPAS1 (Endothelial PAS domain protein 1)
    |
    Welireg (belzutifan)
    2d
    Primary Renal Synovial Sarcoma: A Report of a Rare Case and Management Approach. (PubMed, Cureus)
    Postoperatively, the patient received adjuvant chemotherapy with the AIM (doxorubicin, ifosfamide, and mesna) regimen. Given the extreme rarity of PRSS, we discuss the diagnostic challenges, molecular characteristics, and treatment approach adopted at our institution, contributing to the limited but growing body of knowledge on this rare entity.
    Journal
    |
    SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex)
    |
    doxorubicin hydrochloride • ifosfamide • mesna
    2d
    Diagnostic practice and awareness of SDH- and FH-deficient renal cell carcinoma: results from an Italian Study Group of uropathology (GIUP) survey. (PubMed, Virchows Arch)
    Overall, metabolic RCC recognition in Italy is primarily morphology-driven but constrained by uneven access to confirmatory IHC, particularly 2SC, and to molecular assays. The findings argue for harmonized diagnostic algorithms, regional reference laboratory networks, and routine involvement of molecular tumor boards, supported by targeted educational initiatives (including curated digital slide repositories), to standardize practice and improve patient pathways from morphologic suspicion to genetic counselling and tailored surveillance.
    Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • FH (Fumarate Hydratase)
    3d
    Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study (clinicaltrials.gov)
    P=N/A, N=64, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion